Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Buagafuran clinical trials

Also listed in trial records as AF-5
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 4 trials in our China register that name Buagafuran as an intervention. Synced 10 Nov 2026
4Current trials
2Recruiting now
1Lead sponsor
1Country register
At a glance

Buagafuran is named as an intervention in 4 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Beijing Union Pharmaceutical Factory Ltd. The most-studied condition is Generalized Anxiety Disorder.

Patient leaflets for Buagafuran

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting250%
  • Not yet open250%

Trials by phase

  • Phase 3250%
  • Phase 1250%
01

Clinical trials of Buagafuran

4 trials
StudyPhaseStatusLead sponsorRegisters
Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD
NCT06243614 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder
Phase 3 Recruiting Beijing Union Pharmaceutical Factory Ltd China
Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD
NCT06243640 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder
Phase 3 Recruiting Beijing Union Pharmaceutical Factory Ltd China
Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function
NCT07457190 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder
Phase 1 Not yet open Beijing Union Pharmaceutical Factory Ltd China
Study on the Drug Interaction Between Buagafuran and Voriconazole
NCT07457203 · ClinicalTrials.gov ↗ · Drug Drug Interaction (DDI)
Phase 1 Not yet open Beijing Union Pharmaceutical Factory Ltd China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Buagafuran

2 conditions
Generalized Anxiety Disorder3Drug Drug Interaction (DDI)1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Beijing Union Pharmaceutical Factory Ltd4
04

By country register

RegisterTrialsRecruiting
Clinical trials in China42

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Buagafuran trials

How many clinical trials are testing Buagafuran?

4 current trials in our China register name Buagafuran (also registered as AF-5) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Buagafuran trials recruiting patients?

Yes. 2 of the 4 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Buagafuran clinical trials?

The lead sponsor is Beijing Union Pharmaceutical Factory Ltd. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Buagafuran works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Buagafuran works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Buagafuran (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.